Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis.
about
Targeting microglial K(ATP) channels to treat neurodegenerative diseases: a mitochondrial issueGlibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemiaK(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action via antioxidative pathway activationEffects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.Protective Roles for Potassium SK/K(Ca)2 Channels in Microglia and Neurons.The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia.Glucose pathways adaptation supports acquisition of activated microglia phenotype.Mitochondrial dysfunction in central nervous system white matter disorders.Natural Docosahexaenoic Acid in the Triglyceride Form Attenuates In Vitro Microglial Activation and Ameliorates Autoimmune Encephalomyelitis in Mice.Astroglia-Microglia Cross Talk during Neurodegeneration in the Rat Hippocampus.Microglia is an active player in how glibenclamide improves stroke outcome.Phagocytic microglial phenotype induced by glibenclamide improves functional recovery but worsens hyperalgesia after spinal cord injury in adult rats.Subclinical Doses of ATP-Sensitive Potassium Channel Modulators Prevent Alterations in Memory and Synaptic Plasticity Induced by Amyloid-β.Blockade of microglial KATP -channel abrogates suppression of inflammatory-mediated inhibition of neural precursor cells.Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.
P2860
Q26852041-DEFF640E-3E6E-49F2-B203-FE17578730D9Q29144159-081642FC-606C-445E-AAE9-775B4D5A585CQ34990563-4C87FDEB-692B-4CD0-B1E1-7FCBDB906E02Q36052912-20A5AB77-DFF7-4345-AA15-63D9B51532CAQ36421908-FFA819EB-7BBB-46DD-85F8-CD7FD786EDCCQ36955393-21237360-4BD3-4A97-8027-70836B562485Q38186639-BD2B3A1A-0622-4139-BAFD-C66463719EAFQ38215315-3294B230-0232-41FD-900F-B39EC27BDCB2Q38700383-CA991867-A933-4CFF-80C2-7066FD09CADAQ40249656-DCCDF34E-DFCC-49E9-A169-816C476BA39FQ41809661-7B29F1C0-7C05-4702-8927-AF74640BADA3Q44503785-3817A066-F6BE-4F7B-A65E-224514B14685Q47963951-52CC2BEB-42CB-4F9C-854A-A0879E0A58C5Q48823392-00A0A325-9477-4121-82B4-2A47F523642BQ51144432-07014713-7AE2-4005-B42A-1D559A4890C4
P2860
Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Oral administration of the KAT ...... e model of multiple sclerosis.
@ast
Oral administration of the KAT ...... e model of multiple sclerosis.
@en
type
label
Oral administration of the KAT ...... e model of multiple sclerosis.
@ast
Oral administration of the KAT ...... e model of multiple sclerosis.
@en
prefLabel
Oral administration of the KAT ...... e model of multiple sclerosis.
@ast
Oral administration of the KAT ...... e model of multiple sclerosis.
@en
P2093
P2860
P356
P1476
Oral administration of the KAT ...... e model of multiple sclerosis.
@en
P2093
Andrea Pastén-Zamorano
Javier Gimeno-Bayon
Juan F Espinosa-Parrilla
Manuel J Rodríguez
Marco Pugliese
Nicole Mahy
Noemí Virgili
Pilar Mancera
P2860
P2888
P356
10.1186/1742-2094-8-149
P577
2011-11-02T00:00:00Z
P5875
P6179
1020692883